AstraZeneca
highlights positive phase trial reinforces first in class mechanism of action phase trial met both primary in chronic and nasal polyps multiple indication expansion opportunities significant patient burden in patients with nasal polyps impact on quality of life need for surgery and systemic steroids placebo statistically significant clinically meaningful reduction in size of nasal polyps nasal congestion million patients treated for nasal polyps million with uncontrolled nasal polyps direction severe asthma china primary met crossing eosinophilic esophagitis new phase initiating billion opportunity | AstraZeneca
Company
Deck Type
Deck date
November 2024
Slide
20 of 38
Related slides by other companies
Investor Conference
June 2023
Investor Presentation
March 2023
Investor Presentation
May 2023
Investor Conference
August 2022
Other recent decks by AstraZeneca
Results
February 2025
Results
November 2024
Investor Event
September 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io